Low estrogen receptor (ER) positive breast cancer and neoadjuvant systemic therapy (NAT): Is response similar to ER plus or to ER- disease?

被引：1
|
作者：
Landmann, Alessandra
Farrugia, Daniel J.
Diego, Emilia
Soran, Atilla
Johnson, Ronald
Bonaventura, Marguerite
Dabbs, David J.
Clark, Beth
Brufsky, Adam
Davidson, Nancy E.
Lembersky, Barry C.
Jankowitz, Rachel Catherine
Puhalla, Shannon
Ahrendt, Gretchen M.
McAuliffe, Priscilla F.
Bhargava, Rohit
机构：
[1] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[2] Univ Pittsburgh, Pittsburgh, PA USA
[3] UPMC, Magee Womens Hosp, Pittsburgh, PA USA
[4] Magee Womens Hosp, Pittsburgh, PA USA
[5] Magee Womens Hosp, Dept Path, Pittsburgh, PA USA
[6] NRG Oncol NSABP, Pittsburgh, PA USA
[7] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.580
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
580
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Development of chronic disease model of metastatic estrogen receptor positive (ER plus ) breast cancer (BC)
    Ganapathy, Vidya
    Banach-Petrosky, Whitney
    Xie, Wen
    Nienhuis, Hilde
    Reiss, Michael
    CANCER RESEARCH, 2011, 71
  • [22] National Evaluation of Low Estrogen Receptor Positive Breast Cancer: Similarity of Features and Neoadjuvant Therapy Responses to ER Negative Cancers
    Iorgulescu, Bryan
    Dillon, Deborah
    Brock, Jane
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 131 - 132
  • [23] National Evaluation of Low Estrogen Receptor Positive Breast Cancer: Similarity of Features and Neoadjuvant Therapy Responses to ER Negative Cancers
    Iorgulescu, Bryan
    Dillon, Deborah
    Brock, Jane
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 131 - 132
  • [24] Estrogen-independent effects of ER-α36 in ER-negative breast cancer
    Zhang, Jing
    Li, Guangliang
    Li, Zhongqi
    Yu, Xiongfei
    Zheng, Yi
    Jin, Ketao
    Wang, Haohao
    Gong, Yun
    Sun, Xiaoping
    Teng, Xiaodong
    Cao, Jiang
    Teng, Lisong
    STEROIDS, 2012, 77 (06) : 666 - 673
  • [25] Sex Hormones and Risk of Estrogen Receptor (ER)-Positive and ER-Negative Breast Cancer
    Farhat, G. N.
    Cummings, S. R.
    Parimi, N.
    Huang, A.
    Cauley, J. A.
    Rohan, T. E.
    Hubbell, F. A.
    Vitolins, M.
    Manson, J. E.
    Chlebowski, R. T.
    Lee, J.
    CANCER RESEARCH, 2009, 69 (24) : 533S - 533S
  • [26] Novel dual modulator of estrogen sulfatase and estrogen receptor (ER) for the treatment of ER plus breast cancer.
    Chao, WR
    Peters, RH
    Zaveri, N
    Tanabe, M
    Yamada, Y
    Toko, T
    Asao, T
    Eshima, K
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S103 - S103
  • [27] Human estrogen receptor-α (ER-α) transactivation by selective estrogen receptor modulators (SERMs) on VIT regulatory region in ER-α-negative breast cancer cell line Evsa-T transiently transfected by ER-α
    IP Nyamagana Butera
    S Hadiy
    G Leclercq
    Breast Cancer Research, 3 (Suppl 1)
  • [28] Expression of glucose transporter GLUT-1 and estrogen receptors ER-α and ER-β in human breast cancer
    Laudanski, P
    Koda, M
    Kozlowski, L
    Swiatecka, J
    Wojtukiewicz, M
    Sulkowski, S
    Wolczynski, S
    NEOPLASMA, 2004, 51 (03) : 164 - 168
  • [29] Neoadjuvant endocrine therapy for estrogen receptor (ER) positive breast cancer: Comprehensive systematic review and meta -analysis
    Spring, L.
    Gupta, A.
    Reynolds, K. L.
    Gadd, M. A.
    Isakoff, S. J.
    Ellisen, L. W.
    Moy, B.
    Bardia, A.
    CANCER RESEARCH, 2016, 76
  • [30] Predictors of invasive breast cancer or DCIS recurrence in estrogen receptor positive (ER plus ) and estrogen receptor negative (ER-) ductal carcinoma in situ (DCIS) patients with and without associated invasive carcinoma (IC)
    Picarsic, J.
    Brufsky, A.
    Onisko, A.
    Chivukula, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345